Table 4 Disease activity and inflammatory markers in clinical AID without pathogenic gene variants treated with colchicine
FMF N = 9 | CAPS N = 8 | PFAPA N = 14 | Unclassified AID N = 2 | Total cohort N = 33 | |
|---|---|---|---|---|---|
Disease activity (PGA) in cm (0 to 10 cm), median (range) | |||||
Baseline | 4 (2–5) | 4.5 (3–8) | 4.5 (3–6) | 3.5 (3–4) | 4 (2–8) |
First follow-up | 2 (0–4) | 2.5 (0–4) | 2 (0–5) | 1 (0–2) | 2 (0–5) |
Last follow-up | 1 (0–3) | 1.5 (0–3) | 2 (0–4) | 0.5 (0–1) | 1 (0–4) |
CRP values in mg/dL (N < 0.5 mg/dL) | |||||
Baseline, mean ± SD (tested) | 18 ± 30.35 (9/9) | 14.7 ± 27.49 (8/8) | 8.5 ± 8.72 (14/14) | 0.05 ± 0.06 (2/2) | 12.1 ± 21.28 (33/33) |
First follow-up, mean ± SD (tested) | 1.2 ± 2.15 (8/9) | 2 ± 3.38 (6/8) | 1.7 ± 5.15 (13/14) | 0.01 ± 0.00 (2/2) | 1.5 ± 3.85 (29/33) |
Last follow-up, mean ± SD (tested) | 1.7 ± 3.13 (6/9) | 1 ± 2.55 (8/8) | 3 ± 10.22 (13/14) | 0.49 ± 0.67 (2/2) | 2 ± 7.01 (29/33) |
SAA values in mg/L (N < 10 mg/L) | |||||
Baseline, mean ± SD (tested) | 442.9 ± 668.45 (8/9) | 97.0 ± 117.22 (8/8) | 349.5 ± 320.26 (14/14) | 22.1 ± 28.21 (2/2) | 289.2 ± 410.98 (32/33) |
First follow-up, mean ± SD (tested) | 66.8 ± 147.73 (6/9) | 6.7 ± 9.70 (7/8) | 39.1 ± 95.33 (13/14) | 0.8 ± 0 (1/2) | 35.4 ± 94.42 (27/33) |
Last follow-up, mean ± SD (tested) | 6.7 ± 9.54 (7/9) | 51.7 ± 125.56 (7/8) | 16.9 ± 34.22 (13/14) | 56 ± 77.78 (2/2) | 25.6 ± 66.90 (29/33) |
Proteinuria, N (%) | |||||
Baseline (tested) | 0 (0) (5/9) | 0 (0) (3/8) | 0 (0) (12/14) | 0 (0) (2/2) | 0 (0) (22/33) |
First follow-up (tested) | 0 (0) (6/9) | 0 (0) (5/8) | 0 (0) (10/14) | 0 (0) (2/2) | 0 (0) (23/33) |
Last follow-up (tested) | 0 (0) (7/9) | 0 (0) (7/8) | 0 (0) (11/14) | 0 (0) (2/2) | 0 (0) (27/33) |